CalciMedica, Inc. (CALC): Capital Expenditures
$28.0K
Year ended 2025-12-31
$14.0K
Trailing 12 months to 2026-06-30
+91.3%
3-year compound annual growth
-51.3%
5-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $28.0K | +250.0% | 2026-03-03, From 2025-01-01 |
| 2024-12-31 | $8.0K | -89.7% | 2026-03-03, From 2024-01-01 |
| 2023-12-31 | $78.0K | n/m | 2025-03-27, From 2023-01-01 |
| 2022-12-31 | $4.0K | -99.2% | 2024-03-28, From 2022-01-01 |
| 2021-12-31 | $488.0K | -52.3% | 2023-03-09, From 2021-01-01 |
| 2020-12-31 | $1.02M | +69.1% | 2022-03-11, From 2020-01-01 |
| 2019-12-31 | $605.0K | n/a | 2021-03-05, From 2019-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| CalciMedica, Inc. (CALC) | 2025-12-31 | $28.0K | +250.0% |
| Chemomab Therapeutics Ltd. (CMMB) | 2025-12-31 | $3.0K | n/a |
| Exicure, Inc. (XCUR) | 2025-12-31 | $1.0K | n/a |
| NRX Pharmaceuticals, Inc. (NRXP) | 2024-12-31 | $0 | -100.0% |
| PMGC Holdings Inc. (ELAB) | 2025-12-31 | $442.3K | n/m |
| Propanc Biopharma, Inc. (PPCB) | 2026-06-30 | $4.9K | n/a |
| Cellectar Biosciences, Inc. (CLRB) | 2025-12-31 | $5.9K | -94.4% |
| Imunon, Inc. (IMNN) | 2025-12-31 | $280.6K | +849.8% |
| Cingulate Inc. (CING) | 2025-12-31 | $162.1K | -23.4% |
Compare CALC, CMMB, XCUR, NRXP side by side · Screen every company in Pharmaceutical Preparations ↗